[Management of adverse effects related to human immunoglobulin therapy: Recommendations for clinical practice]

Abstract

Both intravenous and subcutaneous immunoglobulins are therapeutic modalities approved in various conditions, including primary and secondary immune deficiencies and autoimmune disorders. To date, immunoglobulins have more often been considered as a safe medication, with minor adverse effects such as hypertension, fever and chills, nausea, myalgia or headache. However, with the wider use of immunoglobulins in the treatment of autoimmune diseases, severe side effects have also been reported to occur in immunoglobulin-treated patients, especially anaphylaxis, aseptic meningitis, acute renal impairment, thrombotic events as well as haematological manifestations. This paper reviews all the potential adverse events related to immunoglobulin therapy and establishes a comprehensive guideline for the management of these events.

Keywords: Acute renal failure; Complications hématologiques; Hematological complications; Immunoglobulines intraveineuses; Immunoglobulines sous-cutanées; Insuffisance rénale aiguë; Intravenous immunoglobulins; Subcutaneous immunoglobulins; Thromboses; Thrombotic events.